高级检索
当前位置: 首页 > 详情页

Neuroprotective effect of ginkgolide K on glutamate-induced cytotoxicity in PC 12 cells via inhibition of ROS generation and Ca 2+ influx

文献详情

资源类型:
机构: [a]Pharmaceutical Engineering, Institute of Chemistry and Chemical Engineering, Qiqihar University, Qiqihar 161006, China [b]Guangdong Research Institute of Traditional Chinese Medicine, No. 321 Longdong Northern Road, Guangzhou 510009, China [c]School of Pharmacy, South-Central University for Nationalities, Wuhan 430074, China
出处:
ISSN:

关键词: Bax protein Bcl-2 protein Ca 2+ Caspase-3 protein Ginkgolide K PC 12 cells ROS

摘要:
Glutamate is considered to be responsible for the pathogenesis of cerebral ischemia disease. [Ca 2+] i influx and reactive oxygen species (ROS) production are considered to be involved in glutamate-induced apoptosis process. In this study, we investigated the neuroprotective effects of ginkgolide K in the glutamate-induced rat's adrenal pheochromocytoma cell line (PC 12 cells) and the possible mechanism. Glutamate cytotoxicity in PC 12 cells was accompanied by an increment of malondialdehyde (MDA) content and lactate dehydrogenase (LDH) release, as well as Ca 2+ influx, bax/bcl-2 ratio, cytochrome c release, caspase-3 protein and ROS generation, and reduction of cell viability and mitochondrial membrane potential (MMP). Moreover, treatment with glutamate alone resulted in decrease activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) activity. However, pretreatment with ginkgolide K significantly reduced MDA content, LDH release, as well as Ca 2+ influx, cytochrome c release, bax/bcl-2 ratio, caspase-3 protein and ROS production, and attenuated the decrease of cells viability and MMP. In addition, ginkgolide K remarkedly up-regulated SOD and GSH-PX activities. All these findings indicated that ginkgolide K protected PC12 cells against glutamate-induced apoptosis by inhibiting Ca 2+ influx and ROS production. Therefore, the present study supports the notion that ginkgolide K may be a promising neuroprotective agent for the treatment of cerebral ischemia disease. © 2011.

基金:
语种:
中科院(CAS)分区:
出版当年[2011]版:
大类 | 3 区 医学
小类 | 3 区 药学 3 区 毒理学 4 区 神经科学
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 毒理学 3 区 神经科学 3 区 药学
第一作者:
第一作者机构: [a]Pharmaceutical Engineering, Institute of Chemistry and Chemical Engineering, Qiqihar University, Qiqihar 161006, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号